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Abstract
Background: International travel from low-incidence to high-incidence countries for tuberculosis (TB) is regarded as a
risk factor for acquiring TB infection. In this prospective study among long-term travellers we examined the incidence
of TB infection using Interferon gamma release assay (IGRA) test and compared these data with results from a visit to
the TB department to which all long-term travellers were routinely referred.
Methods: Immunocompetent adults, travelling for 13–52 weeks to TB-endemic countries, donated blood pre- and
post-travel for IGRA. The pre-travel IGRA was only tested in case of a positive IGRA post-travel. Results from their visit(s)
to the TB department for TST pre- and post-travel were collected and compared with study results.
Results: We found two IGRA conversions in a group of 516 travellers, resulting in an attack rate (AR) of 0.4% (95% CI:
0.5 - 13.9) and an incidence rate (IR) of 0.85 per 1000 person-months (95% CI: 0.1-3.1).
We found 5 tuberculin skin test (TST) conversions, resulting in AR of 1.9% (5/261; 95% CI: 0.6 - 4.4) and an IR of 4.26 per
1000 person-months (95% CI: 1.38- 9.94). In our study these converters all had a negative IGRA. One traveller however,
who was retested later at the TB department due to a positive TST, then appeared to have seroconverted.
Conclusions: The risk of long-term travellers among our study population acquiring TB infection is low. We conclude
that post-travel IGRA alone could be used for screening for TB infection among long-term travellers to high-endemic
TB countries, but preferably not earlier than 8 weeks after return. One might even argue that IGRA testing should be
limited to only those travellers who are going to work in a medical setting. A person with a positive IGRA should be
referred to a TB physician for further evaluation.
Background
International travel from low-incidence to high-incidence
countries for tuberculosis (TB) is regarded as a risk factor
for acquiring TB infection. This risk increases with the
time spent in a high-incidence country and travellers’
participation in high-risk activities such as working in
healthcare settings [1,2].
A latent TB infection (LTBI) can progress to active, in-
fectious disease. For the majority, the estimated lifetime
risk of developing active TB for individuals with an LTBI
is 10% within the first years after infection [3,4]. Identi-
fying and treating people with (recently acquired) LTBI
is important in disease control, especially in countries
with a low incidence of TB.
For a long time the only available test for detecting
Mycobacterium tuberculosis infection was the tuberculin
skin test (TST). TST has several limitations: intra-
observer variation in reading the results, limited specifi-
city in BCG-vaccinated individuals, false-positive results
due to non-tuberculous mycobacteria, and a boosting
phenomenon if TST is repeated. In addition, TST must
be read after three days, requiring a second healthcare
visit, thus resulting in poor compliance [5].
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Interferon gamma release assay (IGRA), commercially
available since 2005, is an in vitro T-cell based test which
quantifies the immune response of T-cells to in vitro
exposure to antigens of M. tuberculosis, other than those
used in BCG vaccination [6]. A positive test result sug-
gests M. tuberculosis infection. Compared to TST, IGRA
has several advantages: only a single patient visit is re-
quired, results can be available within 24 hours, and there
is no cross reaction with the BCG vaccine or with most
non-tuberculous mycobacteria.
A gold standard for diagnosis of TB infection is absent,
hindering good evaluation of the tests. A review in 2008
investigating the role of IGRAs in screening of travellers,
showed too many limitations to come to a recommenda-
tion. Thus, the advantage of screening travellers by use
of IGRA remains unclear [4].
A previous Dutch study conducted in 1994–1996 dem-
onstrated that the incidence of TB for long-term travellers
(3–12 months) based on TST conversions approaches that
of the local population when travelling to high-incidence
countries [1]. In this prospective study among long-term
travellers we examined the incidence of TB infection using
IGRA and we compared IGRA results with data from the
TB department to which long-term travellers were re-
ferred according to national traveller guidelines.
Methods
Study population
This study was part of a larger prospective mono-centre
study among persons attending the Public Health
Service (PHS) Amsterdam travel clinic in the Department
of Infectious Diseases [7]. All immunocompetent per-
sons ≥18 years and of Dutch or other Western ethnicity
were eligible if they were planning to travel to (sub)tropical
countries for 13–52 weeks. For this sub-study, only partici-
pants who spent ≥13 weeks in a TB-endemic country,
defined as countries with an annual TB incidence
of >50/100,000, were included [8].
Before departure, a standard questionnaire was used
to collect data on socio-demographics, BCG-vaccination
history, travel history (indicated as cumulative time
spent in Asia, Latin America, or Africa during lifetime),
and travel purpose. The study protocol was approved by
the Medical Ethics Committee of the Academic Medical
Center Amsterdam. Participants were included after pro-
viding written informed consent.
Blood samples were taken before and 2–6 weeks after
travel.
For IGRA the QuantiFERON-TB Gold (Cellestis Limited,
Victoria, Australia) was performed following the manufac-
turer’s instruction and was considered positive if ≥ cut-off
point of 0.35 IU/ml. All post-travel samples were tested.
Due to financial constraints only in case of a positive post-
travel sample the pre-travel sample was tested, which had
been stored at −80°C. Positive post-travel samples with
negative pre-travel samples were considered conversions.
TST was performed according to the Mantoux method
with 0.1 ml Purified Protein Derivative (PPD) RT23
(Statens Serum Institute, Copenhagen, Denmark). Ex-
perienced medical staff of the TB department read the
induration between 72 hours and 96 hours. Differences
in induration of ≥10 mm between pre- and post-travel
TST were considered conversions if pre-travel TST
was <10 mm.
Although TST is recommended ≥ 8 weeks post-travel,
participants in this study were referred to the TB depart-
ment for a TST at the same time as the post-travel study
visit. At the TB department, they were either tested and/
or asked to return 8 weeks after travel.
Data analysis was performed with SPSS version 19.0.0.1
(2010, IBM, Somers, USA).
Chi-square tests were used to evaluate predictive value
for TST or IGRA conversion. Tested characteristics in-
cluded: age, sex, BCG, reason for travel, healthcare work,
travel duration, and primary destination.
Incidences were expressed as the rate based on the
person-time spent in endemic countries. Person-time
denominators for converters were divided in half, since
infection was assumed to have occurred halfway during
travel. For travellers with a negative TST post-travel and
an unknown TST pre-travel, we assumed they were
also negative pre-travel. Confidence intervals for both
the attack- and incidence rates have been calculated.
Results
Study population
Between December 2008 and September 2011, 684 per-
sons intending to travel to (sub) tropical countries for 13–
52 weeks provided informed consent. Of these, 168 were
excluded upon completion of the study (Figure 1): 42 trav-
ellers had their travel arrangements changed, 80 had
an itinerary that did not include TB-endemic countries
for ≥13 weeks, 2 were excluded because blood samples
failed, 6 were excluded because they received treat-
ment for TB at the time of study (n = 3) or had a posi-
tive TST in the past for which treatment had been
given (n = 3), and 38 were lost to follow-up. Resulting
in a total of 516 travellers included in this study.
Characteristics
Characteristics are summarised in Table 1. The median
age was 25 years and 35% were female. Mean travel dur-
ation was 22 weeks. Travel purpose was tourism for 62%
of participants, work for 36%, and 2% were visiting friends
or relatives (VFR). Of the 187 persons travelling for (vol-
unteer) work, 20 reported work in a medical setting.
South East Asia was the primary destination for 37%,
South America for 23%, and Sub-Saharan Africa for 22%.
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Mean interval between return from travel, blood donation
and TST was 30 and 50 days respectively.
Results IGRA
Five of all 516 participants had a positive post-travel
IGRA. Of those, three pre-travel samples were already
positive, yielding two conversions (Table 2) and resulting
in an attack rate of 0.4% (2/513; 95% CI: 0.5 -13.9) and
an incidence rate of 0.85 per 1000 person-months (95%
CI: 0.1-3.1). Of the tested characteristics, no risk factors
predictive for IGRA conversions were found. One travel-
ler, number 7 (Table 2), was initially negative but was
tested again later due to a positive TST and appeared
then to have seroconverted.
Results TST
Of the 516 inclusions, 43 had been BCG-vaccinated. Of
the 473 unvaccinated travellers eligible for post-travel
TST, 3 had a TST pre-travel result of ≥ 10 mm and 7 trav-
ellers received a BCG-vaccine pre-travel. After excluding
these 10 participants, 64% (295/463) complied with a
post-travel TST, however 34 did not return to let their
TST result be read.
Of the remaining 261 post-travel TST, 8 were considered
positive. Of these, pre-travel test results were unknown for
3 (non-compliance), resulting in 5 demonstrated and 3 po-
tential conversions (Table 2).
Of the 253 negative post-travel TST 197 had a known
negative TST pre-travel. Assuming that the remaining
56 were also negative pre-travel, we found an attack rate
(AR) of 1.9% (5/261; 95% CI: 0.6 - 4.4) for demonstrated
TST conversions and an incidence rate (IR) of 4.26 per
1000 person-months (95% CI: 1.38- 9.94).
When including potential conversions, we found an
AR of 3.1% (8/261) and an IR of 6.76 per 1000 person-
months (95% CI: 2.9- 13.3).
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Figure 1 Flow chart of study population.
Table 1 Characteristics of 516 travelers to TB-endemic
countries who attended a Dutch travel clinic for pre-travel





Sex Female 336 65
Male 180 35
BCG (before travel) No 473 92
Yes 43 8
Travel history Yes 413 80
No 103 20
Reason for travel Tourism 321 62
Work: non medical setting 95 18
Work: medical setting 20 4
Work: unknown setting 72 14
VFR 8 2
Travel duration Mean, weeks (SD) 21,9 (8.55)
Travel destination
primary
South East Asia 190 37
South America 116 23
Sub-Saharan Africa 111 22




Asia, other 19 3
North Africa/Middle East 1 0.2
Interval between return and blood donation (days)
Mean (SD) 29,8 (16.0)
Interval between return and TST (days) (n = 261)
Mean (SD) 49.8 (36.8)
TB: tuberculosis; SD: standard deviation.
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Table 2 Positive post-travel IGRA* and TST** results in a cohort of 516 travellers to TB-endemic countries, December 2008-September 2011


























SE Asia 365 −0,05 1.15 29 yes nt 8 39 no Volunteer work, non-medical.
TST performed in 2000:
0 mm. Started preventive
treatment 43 days post travel.
2 26-30 no Africa: 1w tourism SE Asia 172 −0,03 0,56 25 yes nt 2 37 no IGRA repeated 85 days post travel:
0.21 IU/ml. No preventive treatment
was started.
3 26-30 no no non medical
work
SE Asia 150 nt −0,01 27 no 2 13 27 yes IGRA repeated 55 days post travel:
0.002 IU/ml. According to Dutch
guidelines: no preventive treatment
was started since IGRA was negative.




SE Asia 356 nt 0,02 28 no 2 15 112 yes No follow-up.
5 18-20 no no tourism SE Asia/
East Asia
93 nt 0,04 38 no 0 11 90 yes No follow-up IGRA. X-ray 94 days
post travel showed no abnormalities;
no preventive treatment.
6 36-40 no Asia: 2 mo
Latin America:
9 mo
tourism South Asia 180 nt −0,05 42 no 0 10 63 yes No follow-up. No preventive
treatment.




118 nt 0,11 18 no 0 10 79 yes Medical student in a hospital in
East-Africa for 3 months. IGRA
repeated 79 days post travel:
7.47 IU/ml; Preventive therapy
was started.





147 nt −0,01 20 no nt 18 20 unknown No IGRA follow-up. X thorax
showed no abnormalities.
No preventive treatment. (TST
performed in 2007 was 6 mm).






242 nt −0,01 51 no nt 11 51 unknown No follow-up. According to Dutch
guidelines: no preventive treatment
was started since IGRA was negative.
10 21- 25 no Africa: 10 mo tourism Central
America
214 nt 0.00 21 no nt 10 61 unknown Advised to have IGRA repeated but
no compliance.



















Comparison of IGRA and TST
Of the 2 travellers with an IGRA conversion, one had a
TST of 8 mm post-travel (unknown pre-travel TST) and
the other was negative (2 mm), tested 39 and 37 days
respectively after return (Table 2). The first has been
treated for TB infection. The latter had the IGRA test
repeated 85 days after return, which was then negative,
and was therefore considered not to have TB infection.
All five TST converted individuals and the 3 potential
conversions (positive TST post-travel but an unknown
pre-travel TST) had a negative post-travel IGRA.
Traveller number 7, who had worked in a hospital in
East-Africa, had a negative IGRA 18 days after return.
At the TB department 79 days after return the TST was
10 mm. The IGRA at that time was also positive (7.47
IU/ml), and therefore treatment for TB infection was
started. This was considered the only confirmed sero-
conversion; of the remaining 7, none were treated for
TB infection.
Discussion
Based on the IGRA test, this prospective study found a
low incidence of recent infection with M tuberculosis
among long-term immunocompetent travellers to TB-
endemic countries; an attack rate (AR) of 0.4% and an in-
cidence rate (IR) of 0.85 per 1000 person-months.
Based on TST conversions, we found an AR of 1.9% and
an IR of 4.3 per 1000 person-months comparable to an
AR of 1.8% and an IR of 3.5 per 1000 person-months in a
previous Dutch study, which had an enrolment period
from 1994 till 1996 [1].
Results of IGRA and TST were not concordant as has
been found in other studies [8-10]. The most likely reason
for a positive TST with a negative IGRA, is a false-positive
TST due to atypical mycobacteria. Another explanation
for this discrepancy in our study could be that occasion-
ally IGRA was tested earlier than TST. Indeed, in one case
in our study (traveller 7, Table 2), a traveller with a nega-
tive pre-travel TST who worked in a medical setting in
East-Africa for 3 months, had a negative IGRA, tested
18 days post travel. Because of the positive TST 11 weeks
post travel, IGRA was repeated at the TB control depart-
ment and turned out to be highly positive (7.47 IU/ml).
This traveller was probably infected in the latter part of
his/her stay in East-Africa. This particular case shows that
it is important not to perform the IGRA earlier than the
TST, which is done at least 8 weeks after return from a
TB-endemic country. That this time interval is important
is also demonstrated in traveller 2, who showed a positive
IGRA tested 3 weeks post travel and a 5 mm TST 5 weeks
post travel. The IGRA was repeated 55 days after return
and appeared to be negative.
As already mentioned in the introduction, there are sev-
eral disadvantages of TST compared to IGRA of which
the poor compliance is an important one [5]. In addition,
compliance for TST was poor in this study at only 56%. A
single IGRA visit is expected to increase the compliance
for screening and a traveller’s own GP can ask for an
IGRA test, which, in contrast to the TST, means that re-
ferral to the TB specialist is not necessary. The estimated
high specificity of IGRA for the diagnosis of LTBI in im-
munocompetent subjects justifies that negative results are
considered true negatives. However, a positive IGRA re-
quires a physician’s careful risk assessment before deciding
to start preventive therapy, which is illustrated by traveller
2 mentioned previously.
The use of IGRA is already known to decrease the num-
ber of people that are recommended preventive treatment
for TB infection: in the Netherlands adding the IGRA test
to the screening protocol (two-step approach of starting
with TST, followed by an IGRA if induration of the TST
is ≥ 5 mm) has led to a decrease of the number of people
who are recommended preventive treatment [11].
Evaluation of the TB department’s follow-up of travellers
with a negative IGRA, performed within the incubation
period, and a positive TST showed that in most cases no
IGRA retesting had taken place, either because the TB
physician found the traveller at low risk for TB infection
or due to non-compliance. However, none of the partici-
pants was registered in the national TB register by the end
of 2013. The only traveller in our study who was consid-
ered to have a true conversion and who was treated for
TB was one of the 20 travellers who reported to have been
working in a medical setting. Therefore one might argue
whether testing for TB should be limited to only those
travellers with potential exposure by working in a medical
setting in TB endemic countries.
Conclusions
We conclude that the risk of acquiring TB infection in im-
munocompetent long-term travellers is low. A post-travel
IGRA alone could be a useful screening tool for TB infec-
tion among long-term travellers to high-endemic TB
countries, arguably even limited to only those travellers
with potential exposure by working in medical settings,
enhancing compliance compared to TST. However, the
IGRA test should be performed at least 8 weeks after re-
turn. A person with a positive IGRA should be referred to
a TB physician for further evaluation.
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